Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8158170 | 0.82 | CYP2C19 (0.64) | EBPSIGMAR1PTPN1CYP2C19KMT2A | |
| SCHEMBL11644679 | 0.79 | GAA (0.64) | EBPSIGMAR1PTPN1CYP2C19KMT2A | |
| SCHEMBL14625066 | 0.79 | KMT2A (0.64) | EBPSIGMAR1PTPN1KMT2AGAA | |
| SCHEMBL7952997 | 0.79 | KMT2A (0.64) | EBPSIGMAR1PTPN1KMT2AGAA | |
| SCHEMBL11482525 | 0.79 | KMT2A (0.64) | EBPSIGMAR1PTPN1KMT2AGAA | |
| SCHEMBL8930342 | 0.79 | MAPT (0.64) | EBPSIGMAR1PTPN1KMT2AGAA | |
| SCHEMBL11482522 | 0.78 | KMT2A (0.59) | EBPSIGMAR1PTPN1KMT2AGAA | |
| SCHEMBL2097539 | 0.78 | EBP (0.65) | EBPSIGMAR1PTPN1CYP2C19KMT2A | |
| SCHEMBL8930340 | 0.78 | KMT2A (0.59) | EBPSIGMAR1PTPN1KMT2AGAA | |
| SCHEMBL7952996 | 0.78 | KMT2A (0.59) | EBPSIGMAR1PTPN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2025-09-18 | — | — | US | claimed |
| CN-104666246-A | Orally Bioavailable Lipid-based Constructs | SDG INC AN OHIO CORPRATION | 2015-06-03 | — | — | CN | claimed |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. (US) | 2011-06-09 | — | — | US | claimed |
| WO-2011022396-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2011-02-24 | — | — | WO | claimed |
| US-7871641-B2 | Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal | SDG, INC. (US) | 2011-01-18 | — | — | US | claimed |
| US-7858116-B2 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. (US) | 2010-12-28 | — | — | US | claimed |
| CN-101917971-A | Orally bioavailable lipid-based structures | SDG INC AN OHIO CORP | 2010-12-15 | — | — | CN | claimed |
| EP-2205217-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (an Ohio Corporation ) (US) | 2010-07-14 | — | — | EP | claimed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | claimed |
| CN-101237854-A | Lipid construct for delivery of insulin to a mammal | SDG INC (US) | 2008-08-06 | — | — | CN | claimed |
| EP-1883394-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2006127361-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | SDG, INC. | 2006-10-05 | — | — | US | claimed |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. | 2006-10-05 | — | — | US | claimed |
| EP-1005327-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| EP-0999855-A1 | POLYMER BASED PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SDG, Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| US-6063400-A | CARRIER; DIAGNOSTIC OR THERAPEUTIC AGENT AND SEQUESTERING AGENT | SDG, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-1999004824-A1 | POLYMER BASED PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SDG, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| WO-1999001110-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 1999-01-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | EBP 939/4885SIGMAR1 67/4885PTPN1 4301/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | EBP 148/4885SIGMAR1 106/4885PTPN1 2936/4885 |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | INSR, GPR119, GCG | EBP 2222/4885SIGMAR1 1887/4885PTPN1 1622/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | EBP 809/4885SIGMAR1 111/4885PTPN1 3485/4885 |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | EBP 892/4885SIGMAR1 830/4885PTPN1 1452/4885 |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | INSR, INSRR, IAPP | EBP 1412/4885SIGMAR1 696/4885PTPN1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.